Selling into a wave of new capacity being built by others: management describes its customers' own build-out spending as
The model's full reasoning — Q1 2018 call → NOWe need to answer YES or NO based on the transcript. The question asks: does management explain the company's current momentum and near-term trajectory chiefly by pointing to a wave of new building, equipping, or capacity-creation being undertaken by other parties — its customers, customers' customers, or institutions in its end markets — for which the company already supplies part of what those parties must buy, AND does management convey that this outside build-out is early or intensifying rather than mature, so that the business it will bring the company is mostly still ahead? We need to check if all three conditions are met: (1) others are building, not just buying; (2) company already in it with real current business; (3) wave is early and big relative to company. Let's analyze the transcript. Management discusses various drivers: sequencing consumables growth, NovaSeq rollout, microarray growth due to direct-to-consumer, population genomics initiatives, oncology partnerships, etc. They talk about customers adopting NovaSeq, but that's more about customers buying instruments and consumables. They mention programs like Genomics England, UK Biobank, NIH precision medicine initiative, etc. These are programs that involve building capacity? For example, Genomics England is sequencing 100,000 genomes, they are halfway. That is a program that is ongoing, but is it "building" capacity? It's more like a project. The question is about "new building, equipping, or capacity-creation being undertaken by other parties" — e.g., customers setting up labs, expanding facilities, etc. Management does mention that customers are forming new companies, e.g., in Australia, China, to do population screening. They also mention that about 25% of NovaSeq orders come from new to Illumina or straight from benchtop customers. That suggests new entrants building capacity. Also, they mention the Human Cell Atlas initiative, but that's research. They mention the Harvard Pilgrim study, but that's a study. They mention the CMS decision and reimbursement, which might lead to more testing, but that's not necessarily building capacity. The key is whether management attributes momentum to a wave of capacity creation by others.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| RDCM | RADCOM Ltd. | Q4 2023 | 2024-01-31 | A |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
TEL · Q4 2023 → YESThe question is about whether management explains the company's current momentum and near-term trajectory by pointing to a wave of new building or capacity-creation by others, that's early or intensif...YES The transcript shows management framing the company's momentum chiefly through a wave of external capacity creation: EV production growth (40% in 2023, expected continued growth next year, with Asia as driver), renewable energy adoption (wind/solar), and AI/cloud applications. They describe others (OEMs, installers 3rd parties) building new productive capability—new EV platforms, renewable sites, AI clusters—while TE already supplies into it via content outperformance and early ramps. Current business is real (sequential order growth, $1.3B pipeline, $100M+ incremental AI revenue). The wave is early/intensifying 2024–2025 (3–4 year programs, more phases ahead, destocking normalizing). This is presented as the primary secular driver offsetting cyclical weakness, not just consumption or pricing. Other elements (destocking, FX) are secondary. Thus all three conditions are met in substance.
ATI · Q1 2018 → YESThe question is about whether management explains the company's current momentum and near-term trajectory by pointing to a wave of new building or capacity-creation by other parties, like customers, t...YES The transcript shows management attributing HPMC momentum chiefly to the "ongoing production ramp of next-generation jet engines at all of our major engine OEM customers" and the "industry is currently in the early phases of a multi-year production expansion." This describes OEMs creating new productive capacity through rate ramps and build growth for next generation engines. Management confirms current business from this wave with "next-generation product sales reached 48% of total jet engine product sales" and "65% increase in next-generation product sales," plus "seventh consecutive quarter of year-over-year margin expansion.
RDCM · Q4 2023 → YESThe question is about whether management explains the company's current momentum and near-term trajectory by pointing to a wave of new building, equipping, or capacity-creation by other parties (custo...YES The transcript shows management framing 2024 momentum around operators’ ongoing 5G standalone network build-outs (new productive capacity being created by customers), with RADCOM already supplying assurance software to those projects and the wave described as still early and accelerating. All three conditions are met in Eyal Harari’s prepared remarks and Q&A.